CHMP backs Zepzelca plus Tecentriq in ES-SCLC
A positive CHMP opinion has moved Immedica’s Zepzelca plus Tecentriq one step closer to European approval for first-line maintenance treatment in extensive-stage small cell lung cancer, or ES-SCLC. The recommendation covers adults whose disease has not progressed after induction therapy with atezolizumab, carboplatin, and etoposide, and it marks another regulatory milestone for a combination that has been gaining traction globally. (biocentury.com)
The decision builds on a broader shift in ES-SCLC treatment over the past several years. Immunotherapy plus platinum-etoposide became a first-line standard after Tecentriq won EU backing in 2019 for initial treatment in this setting, but maintenance options after induction have remained limited. Lurbinectedin, originally developed by PharmaMar and commercialized in different markets through partners including Jazz and Immedica, has steadily expanded its role in small cell lung cancer, including orphan-drug positioning in Europe. (roche.com)
The key evidence comes from the phase 3 IMforte study, which evaluated lurbinectedin plus atezolizumab against atezolizumab alone as maintenance therapy after first-line induction. Jazz said in 2024 that the trial met its primary endpoint and showed statistically significant gains in both progression-free and overall survival. At ASCO 2025, PharmaMar described the data as potentially practice-changing, and secondary reporting from the meeting said the combination reduced the risk of progression or death by 46% versus atezolizumab alone. (nasdaq.com)
Regulatory momentum has continued since then. The FDA approved the combination in October 2025 as the first maintenance treatment for adults with ES-SCLC whose disease had not progressed after induction therapy, and Immedica later announced approval in the United Arab Emirates. Company and investor materials also indicated that the European filing was under EMA review, with an opinion expected in early 2026, which aligns with the timing of this CHMP recommendation. (stocktitan.net)
Industry reaction has framed the regimen as a meaningful advance in a cancer type with historically poor outcomes. Jazz, in announcing the top-line IMforte results, called the survival findings highly encouraging, while meeting coverage and Roche materials have emphasized both efficacy and tolerability in the maintenance setting. Although independent expert commentary tied specifically to the CHMP vote was limited in the sources reviewed, the consistency of messaging across trial presentations, company statements, and follow-up coverage suggests the combination is being positioned as a new standard-building option rather than an incremental add-on. (nasdaq.com)
Why it matters: For oncology clinicians, the practical significance is that maintenance therapy in ES-SCLC may become more active and more structured in Europe if the European Commission confirms the opinion. That could affect sequencing discussions, infusion-center planning, toxicity monitoring, and payer conversations, especially because the eligible population is defined by response or stability after induction rather than by biomarker selection. It may also influence guideline updates and health technology assessment reviews, including in markets such as the UK where NICE has already opened an appraisal track. (nice.org.uk)
There’s also a competitive angle. CHMP has recently backed other ES-SCLC therapies, underscoring how quickly the treatment landscape is moving. For clinicians and health systems, that means more choice, but also more pressure to evaluate comparative value, patient selection, and how newer maintenance or frontline strategies fit alongside emerging agents in relapsed disease. (biocentury.com)
What to watch: The immediate next milestone is a European Commission decision, which EMA documents say normally follows a positive CHMP opinion within about 67 days; after that, national reimbursement reviews, formulary decisions, and guideline updates will determine how quickly patients can actually access the regimen across Europe. (ema.europa.eu)